Neothetics’ injectable salmeterol for double chin, Phase II starts

Neothetics announced that the Phase II proof-of-concept trial, designed to assess LIPO-202 for the reduction of double chin, has initiated. The product is an injectable formulation of salmeterol xinafoate, a ß2-adrenergic receptor agonist commonly used for asthma. LIPO-202 is designed to be locally injected and to activate the ß2-adrenergic receptors on fat cells, triggering the metabolism of triglycerides stored in such cells. The trial is multi-center, randomized, double-blind, placebo-controlled and will assess two different doses of LIPO-202 vs placebo. It will enroll 150 patients in the United States. The study endpoints will include both safety and efficacy measurements. Results are expected in late second quarter 2017.
(Source Globe Newswire)